Does cat's claw reduce inflammation and joint pain?

Cat's claw (Uncaria tomentosa) contains two classes of biologically active compounds that work together to produce its health effects.

Oxindole alkaloids — particularly pentacyclic alkaloids such as isopteropodin, pteropodine, and mitraphylline — are the primary immune-modulating agents. They appear to stimulate white blood cell activity and enhance the body's ability to clear pathogens and damaged cells.

Quinovic acid glycosides and polyphenols provide the primary anti-inflammatory effects. These compounds inhibit NF-κB, a central regulator of the inflammatory response, and reduce production of pro-inflammatory cytokines including TNF-alpha and prostaglandin E2 (PGE2). Importantly, research has shown that the anti-inflammatory activity is independent of alkaloid content — the polyphenols carry significant weight on their own³.

Joint Health

The most consistent clinical evidence is for joint conditions. A 24-week randomized, double-blind trial in 50 patients with rheumatoid arthritis found that a pentacyclic alkaloid extract of cat's claw reduced painful joint count by 53.2% compared to 24.1% with placebo (p = 0.044). Morning stiffness, pain intensity, and joint edema all improved¹.

For osteoarthritis of the knee, freeze-dried cat's claw reduced exercise-related pain significantly within the first week of treatment, with continued improvements in activity scores and physician and patient assessments. Importantly, no adverse effects on blood counts, liver function, or other markers were observed².

Immune Modulation

Cat's claw extracts appear to influence immune function in a nuanced way — stimulating certain immune responses while dampening excessive inflammation. This dual action may be relevant to autoimmune conditions, where overstimulation of the immune system causes tissue damage. Laboratory studies show cat's claw can inhibit TNF-alpha by up to 5.5-fold in stimulated immune cells³.

A 2024 systematic review and meta-analysis of in vivo studies confirmed that aqueous and hydroethanolic extracts consistently reduced NF-κB activity and inflammatory markers, while showing low toxicity across study designs⁴.

Dosage and Forms

• Standardized extract (pentacyclic alkaloid type): 250–350 mg per day is the most studied dosage range for joint conditions
• Aqueous inner bark extract: 1–4 g per day in capsule form
• Tea: traditionally prepared from 1–2 g of dried inner bark per cup

Two chemotypes of Uncaria tomentosa exist — one rich in pentacyclic alkaloids (immune-supportive) and one in tetracyclic alkaloids (which may interfere with the pentacyclic type's effects). Reputable supplements specify the pentacyclic alkaloid chemotype.

Practical Notes

Cat's claw is generally considered safe at standard doses. It should be avoided during pregnancy (due to traditional use as a contraceptive), and used cautiously alongside immunosuppressive medications, anticoagulants, or blood pressure drugs, as interactions are possible. The NIH notes that liver injury has been reported rarely, typically with very high doses or prolonged use⁶.

It pairs naturally with other anti-inflammatory herbs. See our Turmeric page and our Quercetin page for related approaches to managing chronic inflammation.

Rheumatoid Arthritis: Randomized Controlled Trial

Mur et al. (2002) conducted a 52-week randomized, double-blind trial comparing a standardized pentacyclic alkaloid-chemotype extract of Uncaria tomentosa to placebo in 40 active rheumatoid arthritis patients (PMID 11950006). The first 24 weeks were placebo-controlled; in the second phase, patients crossed to treatment. After 24 weeks, the treatment group showed a 53.2% reduction in painful joints versus 24.1% in the placebo group (p = 0.044). Secondary outcomes including morning stiffness, patient pain assessment, and physician global assessment also trended toward improvement, though not all reached statistical significance. The study used the DAS-28 scoring system. The extract was well-tolerated with no significant adverse events reported.

Osteoarthritis: Mechanistic and Clinical Study

Piscoya et al. (2001) evaluated freeze-dried Uncaria guianensis (a closely related species) in 45 patients with knee osteoarthritis in a randomized, double-blind, placebo-controlled design (PMID 11603848). Pain associated with activity was the primary outcome, measured by visual analog scale and Lequesne index. Benefits were apparent within the first week of treatment. Laboratory work identified inhibition of TNF-alpha and, to a lesser extent, PGE2 as key mechanisms of action. Complete blood counts and liver function tests were unchanged from baseline in treated patients, confirming the safety profile.

Anti-Inflammatory Mechanisms: Independent of Alkaloids

Sandoval et al. (2002) investigated whether the anti-inflammatory effects of cat's claw required its alkaloid content (PMID 12120814). Using LPS-stimulated macrophage models and several cat's claw preparations with varying alkaloid concentrations, they found that anti-inflammatory and antioxidant activity persisted even in alkaloid-depleted fractions. This implicated the polyphenol fraction — including quinovic acid glycosides, tannins, and catechins — as primary mediators of anti-inflammatory effects. The study used standard measures including TNF-alpha production and lipid peroxidation assays.

Systematic Review and Meta-Analysis (2024)

A comprehensive systematic review published in Frontiers in Pharmacology (PMID 38881881) analyzed preclinical in vivo studies of Uncaria tomentosa extracts for anti-inflammatory and immunomodulatory activity. Four studies using aqueous and hydroethanolic extracts demonstrated significant NF-κB reduction. Across included studies, the extracts showed dose-dependent effects on inflammatory markers and consistently low toxicity profiles. The authors concluded that preclinical evidence is robust and called for more rigorously designed clinical trials — particularly for chronic inflammatory conditions beyond rheumatoid arthritis and osteoarthritis.

Quality of Life in Cancer Patients

de Paula et al. (2014) ran a prospective phase II study of a dry extract of Uncaria tomentosa (100 mg three times a day) in 51 patients with advanced solid tumors who had no further therapeutic options⁵. Compared with baseline, overall quality of life (p = 0.041) and social functioning (p = 0.034) improved on the EORTC QLQ-C-30 scale, and fatigue fell on the Chalder Fatigue Questionnaire (p = 0.050). None of the inflammatory or biochemical markers measured changed significantly, no tumor response was detected, and the disease stabilized for more than 8 months in four participants. The authors concluded that the mechanism does not appear to be related to the plant's anti-inflammatory properties. This was an exploratory single-group study, so it cannot separate a real effect from placebo response, and it was not designed to assess tumor outcomes.

Strength of Evidence

The evidence base for cat's claw is moderately strong for joint pain conditions. Two small but well-designed randomized controlled trials support its use for rheumatoid arthritis and knee osteoarthritis, and the mechanistic literature is coherent: NF-κB inhibition, TNF-alpha reduction, and antioxidant activity are all well-documented. Limitations include small sample sizes in most clinical trials, short follow-up periods, and variation in extracts used across studies. The 2024 systematic review reinforces confidence in the anti-inflammatory mechanism while acknowledging the need for larger trials. Overall, the evidence supports cat's claw as a reasonable adjunct for inflammation management with an established safety record at conventional doses.